Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.67
DSCO's Cash to Debt is ranked higher than
66% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. DSCO: 4.67 )
DSCO' s 10-Year Cash to Debt Range
Min: 1.37   Max: No Debt
Current: 4.67

Equity to Asset 0.66
DSCO's Equity to Asset is ranked higher than
71% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DSCO: 0.66 )
DSCO' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.9
Current: 0.66

0.1
0.9
F-Score: 3
Z-Score: -4.32
M-Score: -4.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -11471.13
DSCO's Operating margin (%) is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. DSCO: -11471.13 )
DSCO' s 10-Year Operating margin (%) Range
Min: -619900   Max: -834.65
Current: -11471.13

-619900
-834.65
Net-margin (%) -11653.35
DSCO's Net-margin (%) is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. DSCO: -11653.35 )
DSCO' s 10-Year Net-margin (%) Range
Min: -920000   Max: -850.13
Current: -11653.35

-920000
-850.13
ROE (%) -77.29
DSCO's ROE (%) is ranked higher than
57% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. DSCO: -77.29 )
DSCO' s 10-Year ROE (%) Range
Min: -2304.86   Max: -63.25
Current: -77.29

-2304.86
-63.25
ROA (%) -50.62
DSCO's ROA (%) is ranked higher than
60% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. DSCO: -50.62 )
DSCO' s 10-Year ROA (%) Range
Min: -305.88   Max: -50.62
Current: -50.62

-305.88
-50.62
ROC (Joel Greenblatt) (%) -2687.68
DSCO's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. DSCO: -2687.68 )
DSCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2687.68   Max: -63.16
Current: -2687.68

-2687.68
-63.16
EBITDA Growth (%) -19.40
DSCO's EBITDA Growth (%) is ranked higher than
66% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. DSCO: -19.40 )
DSCO' s 10-Year EBITDA Growth (%) Range
Min: -55   Max: 22.5
Current: -19.4

-55
22.5
EPS Growth (%) -20.80
DSCO's EPS Growth (%) is ranked higher than
66% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. DSCO: -20.80 )
DSCO' s 10-Year EPS Growth (%) Range
Min: -61.7   Max: 25.5
Current: -20.8

-61.7
25.5
» DSCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DSCO Guru Trades in

Q2 2012

DSCO Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q2 2013

DSCO Guru Trades in Q2 2013

Jim Simons 12,392 sh (New)
» More
Q3 2013

DSCO Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DSCO



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
DSCO's P/B is ranked higher than
76% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. DSCO: 2.60 )
DSCO' s 10-Year P/B Range
Min: 0.84   Max: 31.91
Current: 2.6

0.84
31.91
P/S 270.30
DSCO's P/S is ranked lower than
89% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. DSCO: 270.30 )
DSCO' s 10-Year P/S Range
Min: 0   Max: 2420.98
Current: 270.3

0
2420.98
EV-to-EBIT 0.10
DSCO's EV-to-EBIT is ranked higher than
100% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. DSCO: 0.10 )
DSCO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
DSCO's Price/Net Cash is ranked higher than
87% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. DSCO: 2.80 )
DSCO' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 40
Current: 2.8

1.2
40
Price/Net Current Asset Value 2.80
DSCO's Price/Net Current Asset Value is ranked higher than
89% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. DSCO: 2.80 )
DSCO' s 10-Year Price/Net Current Asset Value Range
Min: 1.2   Max: 40
Current: 2.8

1.2
40
Price/Tangible Book 2.60
DSCO's Price/Tangible Book is ranked higher than
80% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. DSCO: 2.60 )
DSCO' s 10-Year Price/Tangible Book Range
Min: 0.48   Max: 62.85
Current: 2.6

0.48
62.85
Price/Median PS Value 0.70
DSCO's Price/Median PS Value is ranked higher than
83% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. DSCO: 0.70 )
DSCO' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 22.02
Current: 0.7

0.03
22.02
Earnings Yield (Greenblatt) 1060.80
DSCO's Earnings Yield (Greenblatt) is ranked higher than
97% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. DSCO: 1060.80 )
DSCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 1343.2
Current: 1060.8

1.1
1343.2
Forward Rate of Return (Yacktman) -122.88
DSCO's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. DSCO: -122.88 )
DSCO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 38.6   Max: 49.8
Current: -122.88

38.6
49.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYBN.Germany
Discovery Laboratories, Inc. was incorporated in the state of Delaware in 1992. The company is a biotechnology Company developing Surfactant Replacement Therapies to treat respiratory disorders and diseases for which there frequently are few or no approved therapies. The company's novel proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant, KL4 Surfactant that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for survival and normal respiratory function. In addition, its proprietary Capillary Aerosolization Technology produces a dense aerosol with a defined particle size, to potentially deliver its aerosolized KL4 Surfactant to the deep lung. Discovery is currently focused on developing its products, Surfaxin(r), Surfaxin LS(tm) and Aerosurf(r), to address the most respiratory conditions affecting pediatric populations. Surfaxin, its first product based on its novel KL4 Surfactant Technology, if approved, would represent the first synthetic, peptide-containing surfactant for use in pediatric medicine. It has filed with the U.S. Food and Drug Administration a New Drug Application for Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome in premature infants. Aerosurf is its proprietary KL4 Surfactant in aerosolized form, which it is developing using its Capillary Aerosolization Technology initially to treat premature infants at risk for RDS. Aerosurf, if approved, would be possible to administer surfactant into the deep lung without subjecting patients to such invasive procedures. Aerosurf has the potential to enable a potentially increase in the use of SRT in pediatric medicine. The Company plans over time to develop its KL4 Surfactant Technology into a robust pipeline of products that would potentially address a variety of debilitating respiratory conditions in a range of patient populations, from premature infants to adults, that suffer from severe and debilitating respiratory conditions for which there currently are few or no approved therapies. Its programs include development of Surfaxin to potentially address Bronchopulmonary Dysplasia) in premature infants and Acute Respiratory Failure in children, and the conduction of research and development with its KL4 Surfactant to potentially address Cystic Fibrosis, Acute Lung Injury, and other diseases associated with inflammation of the lung, such as Asthma and Chronic Obstructive Pulmonary Disease.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide